Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin.
An overview of the mechanism of action, dosing, clinical indications, and toxicities of the glycopeptide vancomycin is provided. The emerging gram-positive bacterial resistance to antimicrobials and its mechanisms are reviewed. Strategies to control this emergence of resistance are expected to be proposed. Newer antimicrobial agents that have activity against vancomycin-resistant organisms are now available and play a critical role in the treatment of life-threatening infections.
Nailor
Michael D
MD
Department of Internal Medicine, Wayne State University, Detroit, MI 48201, USA.
Sobel
Jack D
JD
D000617:Aminoglycosides / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017576:Daptomycin / Q000627:therapeutic use; D006020:Glycopeptides / Q000627:therapeutic use*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D000077427:Lipoglycopeptides; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D017334:Teicoplanin / Q000031:analogs & derivatives / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use; D014769:Virginiamycin / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D010456:Peptides, Cyclic; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D017334:Teicoplanin; D014640:Vancomycin; C469289:dalbavancin; D017576:Daptomycin; C487637:telavancin